Human Continuum has announced the appointment of Dr Omar Khalid Sial as Chief Scientific Officer (CSO).
Sial brings significant expertise in neuroscience, immunology and genetics to his new role. His previous work in preclinical research and the development of new drugs includes end-to-end experience, from drug discovery to real-world treatment applications. He previously held the position of postdoctoral associate at the University of Florida (UF) Scripps Biomedical Research Institute, during which time he studied orphan receptor biology and the intra- and extracellular mechanisms of signal transduction.
Other previous experience includes research work at the Icahn School of Medicine at Mount Sinai and consultancy work at Stream Biomedical. Sial has been consistently recognised throughout his career for his commitment to research, and has authored multiple peer-reviewed publications for major journals.
Sean Law, CEO and board member of Human Continuum, said: “The addition of a researcher of Omar’s calibre represents a significant step forward for the company. His deep technical expertise and disciplined approach will be instrumental in advancing our portfolio of biologic formulations and exosome-based therapeutics through their development pipeline.”